|
News
NeuroMatters: A Research Publication of Colorado Neurological Institute
Volume 1 | Issue 1 | Fall 2011
Focus of this Issue: Movement Disorders
 A Comprehensive, Patient-Focused Center of Excellence
At the Colorado Neurological Institute, clinical research is central to our mission and work. The many FDA-approved investigational treatments offered at the Colorado Neurological Institute, and through our longstanding partnership with Swedish Medical Center and the HealthONE system, make CNI a leading center for clinical research in the neurosciences. While most patients access CNI studies through the inpatient setting, many are referred here by providers from across the Rocky Mountain region and beyond. Read more.
State-of-the Art Treatments for Movement Disorders
Rajeev Kumar, MD, FRCPC, Medical Director, CNI Movement Disorders Center
Movement disorders are neurologic diseases predominantly involving the basal ganglia. Hyperkinetic movement disorders, which cause excessive movement, include Huntington's disease and dystonia. Hypokinetic disorders, which cause a reduction in movement, include Parkinson's disease and progressive supranuclear palsy (PSP). The Colorado Neurological Institute Movement Disorders Center has been at the forefront of state-of-the-art treatments, emerging research and education for over 20 years. Our research includes independent, single-center studies and also participation in NIH-sponsored and pharmaceutical-sponsored multi-center clinical trials. Read more.
Current Parkinson's Disease Studies
The CNI Movement Disorders Center is studying new medications that may slow the progression of Parkinson’s disease (PD), treat symptoms of early disease, and reduce motor fluctuations and dyskinesia in advanced patients. These include the following...Read more.
The Gift of Participation: A Patient’s Perspective
Diane G. Cook
Let’s suppose you have Parkinson’s disease. And let’s suppose I tell you that you are contributing to the delay in developing a cure for this disease. You would be aghast, wouldn’t you? But that’s just what is happening today in the PD community. Nine out of 10 clinical trials are delayed because only one in 100 people with Parkinson’s disease participates in research. Read more.
When Every Second Counts
Christopher V. Fanale, MD, Medical Director, CNI Stroke Program; Medical Director, CO-DOC Telemedicine Program
When treating a stroke patient, every second counts. Founded in 2006, the CO-DOC Telemedicine Program was a concept I brought to Colorado from my stroke fellowship at the University of California, San Diego. CO-DOC, which stands for Collaborative Digital Online Consultant, enables rapid diagnosis and treatment recommendations for patients experiencing strokes in communities that do not have access to round-the-clock specialty care. Read more.
Huntington’s Disease Studies
Huntington’s disease (HD) is an autosomaldominant neuro-degenerative disorder characterized by progressive movement problems (chorea followed by Parkinsonism and dystonia), dementia, and psychiatric problems. The CNI Movement Disorders Center works with the Huntington Study Group to better-understand the pathogenesis of the disease and develop treatments which may slow progression. Current HD studies at CNI include...Read more.
Center for Hearing Presents at Cochlear Implant Symposium
David C. Kelsall, MD, Medical Director, CNI Center for Hearing
The Colorado Neurological Institute Center for Hearing’s Rocky Mountain Cochlear Implant Center offers cutting-edge technology and is a major research facility for the development of current cochlear implant devices, techniques and outcomes. Our studies include both independent, single-center investigations and manufacturer-sponsored, multicenter clinical trials. Read more.
Progressive Supranuclear Palsy Studies
Progressive Supranuclear Palsy (PSP) is a progressive atypical Parkinsonian syndrome that responds poorly to levodopa and is usually accompanied by progressive eye movement and balance problems. Severe disability and death usually result within 5-10 years. There is no current treatment to slow or stop the progression of PSP. Read more.
Case Study: Adherus™ Dural Sealant System Study
G. Alexander West, MD, PhD, Medical Director, CNI Center for Brain & Spinal Tumors
Cerebrospinal fluid leakage following neurosurgery is a common concern. A clear fluid found in the brain and spinal cord, CSF protects and nourishes and is contained by the dura mater. During neurosurgical procedures, the dura mater is often intentionally opened to provide access to the cerebrum. In other cases, the dura may also be accidentally torn, shrink back as a result of desiccation, or be destroyed by tumor invasion. Read more.
Superior Survival in Glioblastoma Patients
Edward B. Arenson, MD, Founding Director, CNI Center for Brain & Spinal Tumors
It is well documented that combinations of effective chemotherapy drugs are critical to effective cancer treatment. Without such a combination of chemotherapy drugs, cancer is all but incurable. With this in mind, beginning in 1999 the CNI Center for Brain & Spinal Tumors began treating patients with newly diagnosed glioblastoma with a 3-drug combination called BITE. Read more.
|
